A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Tuesday. The fund bought over 240,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE) altogether, as the price of these ETFs were somewhat mixed on the day. Note that these funds are up significantly in the past year.
Specifically, ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 55,163 shares of Fate Therapeutics, and ARK Innovation ETF (NYSEARCA: ARKK | ARKK Price Prediction) bought 186,114 shares. At Tuesday’s closing price, this would have valued this purchase at roughly $20.1 million altogether. Even though this is a small fraction of the total holdings, every little bit counts. ARKG is up 50% in the past year and ARKK is up closer to 46%.
Here is a look at the other purchases across the ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | ETSY | Etsy | 90,831 |
| ARKF | HOOD | Robinhood Markets | 89,622 |
| ARKG | SRNG | Soaring Eagle Acquisition | 214,751 |
| ARKG | SMFR | Sema4 | 96,000 |
| ARKG | SGFY | Signify Health | 31,587 |
| ARKG | RPTX | Repare Therapeutics | 11,809 |
| ARKG | MASS | 908 Devices | 46,488 |
| ARKG | BEAM | Beam Therapeutics | 3,074 |
| ARKG | EDIT | Editas Medicine | 35,000 |
| ARKG | FATE | Fate Therapeutics | 55,163 |
| ARKK | VCYT | Veracyte | 16,379 |
| ARKK | PACB | Pacific Biosciences of California | 190,000 |
| ARKK | FATE | Fate Therapeutics | 186,114 |
| ARKK | BEAM | Beam Therapeutics | 37,694 |
| ARKQ | MKFG | Markforged | 397,767 |
| ARKQ | AVAV | Aerovironment | 22,232 |
| ARKW | CND | Conchord Acquisition | 3,000 |
| ARKW | KVSB | Khosla Ventures Acquisition II | 10,000 |
| ARKW | VUZI | Vuzix | 90,000 |
[nativounit]
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=927148][wallst_email_signup]
Top Gaining Stocks
Top Losing Stocks